Razelle Kurzrock

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:2458-65. 2010
  2. ncbi Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:6144-51. 2012
  3. ncbi Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways
    Laura S Angelo
    Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 10:2094-103. 2011
  4. ncbi Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 11:308-16. 2012
  5. ncbi Cytokine deregulation in cancer
    R Kurzrock
    Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Biomed Pharmacother 55:543-7. 2001
  6. ncbi Project Zero Delay: a process for accelerating the activation of cancer clinical trials
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, M D Anderson Cancer Center, Unit 455, PO Box 301402 Houston, TX 77030, USA
    J Clin Oncol 27:4433-40. 2009
  7. ncbi Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics
    Razelle Kurzrock
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, Texas 77030, USA
    Ann Intern Med 138:819-30. 2003
  8. ncbi Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance
    Razelle Kurzrock
    Division of Cancer Medicine, The University of Texas, M D Anderson Cancver Center, Houston, Texas 77230 1402, USA
    Leuk Lymphoma 47:1651-64. 2006
  9. ncbi Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
    Razelle Kurzrock
    Department of Bioimmunotherapy, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:4527-34. 2003
  10. ncbi Purine analogues in advanced T-cell lymphoid malignancies
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 43:S27-34. 2006

Research Grants

  1. Farnesyltransferase Inhibitor Therapy for Myelodysplasia
    Razelle Kurzrock; Fiscal Year: 2002
  2. Exploratory Trial of Curcumin in Pancreatic Cancer
    Razelle Kurzrock; Fiscal Year: 2005
  3. Phase I Studies of Targeted Anti-Cancer Therapies
    Razelle Kurzrock; Fiscal Year: 2007

Detail Information

Publications145 found, 100 shown here

  1. ncbi A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 16:2458-65. 2010
    ..Subsequent cohorts were dosed at 3 and then 9 mg/kg. An additional 12 patients received 9 mg/kg R1507 qW. Patients remained on the study until the development of a dose-limiting toxicity or progressive disease...
  2. ncbi Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:6144-51. 2012
    ..In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN-2208 in adult patients with advanced solid tumors...
  3. ncbi Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways
    Laura S Angelo
    Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 10:2094-103. 2011
    ..The combination of curcumin and an hsp inhibitor synergistically suppressed schwannoma cell growth. Our results provide a rationale for combining curcumin and KNK437 in the treatment of NF2...
  4. ncbi Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 11:308-16. 2012
    ..GRN1005 was well tolerated and showed activity in heavily pretreated patients with advanced solid tumors, including those who had brain metastases and/or failed prior taxane therapy...
  5. ncbi Cytokine deregulation in cancer
    R Kurzrock
    Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Biomed Pharmacother 55:543-7. 2001
    ..The molecular mechanisms underlying cytokine deregulation are now being investigated, with preliminary data suggesting heterogeneous genetic driving forces, including oncogene aberrations and viral infection...
  6. ncbi Project Zero Delay: a process for accelerating the activation of cancer clinical trials
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, M D Anderson Cancer Center, Unit 455, PO Box 301402 Houston, TX 77030, USA
    J Clin Oncol 27:4433-40. 2009
    ..Eliminating administrative delays can accelerate the evaluation of new drugs without compromising patient safety or the quality of clinical research...
  7. ncbi Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics
    Razelle Kurzrock
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, Texas 77030, USA
    Ann Intern Med 138:819-30. 2003
    ..This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach...
  8. ncbi Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance
    Razelle Kurzrock
    Division of Cancer Medicine, The University of Texas, M D Anderson Cancver Center, Houston, Texas 77230 1402, USA
    Leuk Lymphoma 47:1651-64. 2006
    ....
  9. ncbi Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
    Razelle Kurzrock
    Department of Bioimmunotherapy, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:4527-34. 2003
    ..09). We conclude that, at doses that are well tolerated, R115777 markedly inhibits the FTase target and has antitumor activity in MDS...
  10. ncbi Purine analogues in advanced T-cell lymphoid malignancies
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 43:S27-34. 2006
    ..Future studies of purine analogues should evaluate patients who are less heavily pretreated and combination therapy with other agents such as alemtuzumab should be investigated in order to prolong the duration of disease remission...
  11. ncbi Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:1287-92. 2004
    ....
  12. ncbi Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited
    Razelle Kurzrock
    Department of Bioimmunotherapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:1361-7. 2005
    ....
  13. ncbi Studies in target-based treatment
    Razelle Kurzrock
    Phase I Program, Division of Cancer Medicine, Unit 422, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 6:1477. 2007
    ....
  14. ncbi Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
    Razelle Kurzrock
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 29:2660-6. 2011
    ..Early observations of clinical benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article...
  15. ncbi Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome
    Razelle Kurzrock
    Phase I Program, University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Cancer Res 14:509-14. 2008
    ..To determine the safety and describe the antitumor activity of tipifarnib in patients with myelodysplastic syndrome (MDS) using an alternate-week schedule...
  16. ncbi Therapy of T cell lymphomas with pentostatin
    R Kurzrock
    Department of Bioimmunotherapy, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Ann N Y Acad Sci 941:200-5. 2001
    ..These observations suggest that further exploration of this agent, in combination with other drugs active in T cell lymphomas, is warranted in this group of diseases...
  17. ncbi Studies in target-based treatment
    Razelle Kurzrock
    Phase I Program, Division of Cancer Medicine, Unit 422, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA
    Mol Cancer Ther 6:2385. 2007
  18. ncbi Cutaneous castleman's disease responds to anti interleukin-6 treatment
    Bilal Ahmed
    Phase I Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, TX 77030, USA
    Mol Cancer Ther 6:2386-90. 2007
    ..Therefore, our patient was treated with CNTO328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses...
  19. ncbi I have good news! You have leukemia
    Razelle Kurzrock
    Phase I Program, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Clin Dermatol 25:350-2. 2007
  20. ncbi Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
    ....
  21. ncbi Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model
    Jing Gong
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2239-47. 2009
    ..This type of agent merits investigation in the clinic to determine if it can predict patient responses to kinase inhibitors based on phosphokinase imaging...
  22. ncbi Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 66:1087-93. 2010
    ..We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement...
  23. ncbi Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6373-83. 2012
    ..We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations...
  24. ncbi Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 379:1893-901. 2012
    ..We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours, especially those with melanoma and untreated, asymptomatic brain metastases...
  25. ncbi Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
    Jorge Cortes
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 101:1692-7. 2003
    ..R115777 showed clinical activity in patients with CML and MF. The effect on VEGF needs to be further investigated to determine whether this might be a possible mechanism of action of R115777...
  26. ncbi Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    Apostolia M Tsimberidou
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
    J Clin Oncol 26:196-203. 2008
    ..We conducted a phase I-II trial of oxaliplatin, fludarabine, cytarabine, and rituximab (OFAR) in these diseases...
  27. ncbi Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases
    Luis H Camacho
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Colorectal Cancer 9:311-4. 2010
    ....
  28. ncbi Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes
    Cielito C Reyes-Gibby
    Department of Epidemiology, Division of Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Pain Symptom Manage 38:894-902. 2009
    ..23, 95% CI=1.4, 4.7) for severe pain relative to the AA genotypes. We provide preliminary evidence of the role of IL-8 in the severity of pain in pancreatic cancer patients. Additional studies are needed in larger cohorts of patients...
  29. ncbi The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care
    Cielito C Reyes-Gibby
    Department of Epidemiology, Division of Cancer Prevention, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street Unit 1340, Houston, TX 77030 4009, USA
    Cancer Epidemiol Biomarkers Prev 17:3262-7. 2008
    ....
  30. ncbi Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy
    Henrique A Parsons
    Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Nutr Cancer 64:206-17. 2012
    ..171). In conclusion, body composition was not significantly associated with toxicities or survival in our small sample...
  31. ncbi Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience
    Christos Vaklavas
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 117:77-85. 2011
    ..The purpose of this study was to report the presenting characteristics and outcomes of patients with locally advanced or metastatic pancreatic cancer treated on phase 1 clinical trials at a single institution...
  32. ncbi A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:4086-94. 2010
    ..The authors of this report conducted a phase 1 study of hepatic arterial infusion (HAI) oxaliplatin combination therapy in patients with advanced cancer and liver metastases...
  33. ncbi KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
    ..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents...
  34. ncbi A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
    John W Moroney
    Department of Gynecology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:6840-6. 2011
    ..We, therefore, added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates...
  35. ncbi Phase II study of alemtuzumab in chronic lymphoproliferative disorders
    Alessandra Ferrajoli
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:773-8. 2003
    ..Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders...
  36. ncbi Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:247-53. 2011
    ..The survival of patients with liver metastases from solid tumors is poor. We conducted a phase I study of hepatic arterial infusion (HAI) paclitaxel in patients with advanced cancer and predominant liver involvement...
  37. ncbi A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer
    Stacy Moulder
    Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Unit 1354, 1155 Pressler Street, Houston, TX 77030, USA
    Invest New Drugs 28:634-40. 2010
    ..This trial was designed to establish the maximum tolerated dose (MTD) of imexon given with docetaxel in breast, prostate and non-small cell lung cancer (NSCLC)...
  38. ncbi PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:276-84. 2013
    ..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration...
  39. ncbi Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver
    Apostolia M Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 71:389-97. 2013
    ..Liver metastases in patients with cancer are associated with poor survival. We hypothesized that hepatic arterial infusion (HAI) of oxaliplatin combination therapy would have antitumor activity in these patients...
  40. ncbi A phase i first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas
    David S Hong
    Department ofInvestigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:3396-406. 2012
    ....
  41. ncbi Salirasib in the treatment of pancreatic cancer
    Ernesto Bustinza-Linares
    Department of Investigational Cancer Therapeutics, The Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Future Oncol 6:885-91. 2010
    ..7 months. Future studies will determine whether salirasib adds to the anti-tumor activity of drugs approved by the US FDA for pancreatic cancer...
  42. ncbi Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Gynecol Oncol 126:47-53. 2012
    ..On the basis of reversal of taxane resistance with AKT inhibition, we initiated a phase I trial of the AKT inhibitor perifosine with docetaxel in taxane and platinum-resistant or refractory epithelial ovarian cancer...
  43. ncbi Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies
    David S Hong
    Division of Cancer Medicine, Department of Investigational Therapeutics Phase 1 Program, Unit 455, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 15:7061-8. 2009
    ....
  44. ncbi Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer
    Lan Li
    Phase I Program, Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 6:1276-82. 2007
    ..We are currently developing liposomal curcumin for introduction into the clinical setting...
  45. ncbi The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:1605-13. 2008
    ..In the current study, the authors assessed the association between serum levels of various cytokines and clinical outcomes in patients with untreated AML or high-risk MDS...
  46. ncbi PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
    ..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis...
  47. ncbi Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib
    David S Hong
    Phase I Program, Department of Investigational Cancer Therapeutics, Unit 455, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Dermatol 144:779-82. 2008
    ....
  48. ncbi A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
    David S Hong
    MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 18:4173-82. 2012
    ..The objectives of the study were to evaluate the maximum tolerated dose (MTD), safety, pharmacodynamics, pharmacokinetics, and antitumor activity of PX-866 in patients with incurable cancers...
  49. ncbi Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Biostatistics, and Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2922-9. 2012
    ....
  50. ncbi Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:2625-31. 2012
    ..Temsirolimus was combined with cixutumumab, a fully human IgG1 monoclonal antibody directed at the insulin growth factor-1 receptor (IGF-1R)...
  51. ncbi PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
    ..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance...
  52. ncbi Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
    Jorge Cortes
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:2805-12. 2005
    ..To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS)...
  53. ncbi Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:4423-32. 2009
    ..Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed...
  54. ncbi Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
    ..The outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated in phase I clinical trials have not been systematically analyzed...
  55. ncbi Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Clin Breast Cancer 10:46-51. 2010
    ..Patients with metastatic breast cancer (MBC) refractory to standard therapy have a poor prognosis. We assessed prognostic factors and clinical outcomes for patients with MBC referred to a phase I clinic focused primarily on targeted agents...
  56. ncbi Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies
    David S Hong
    Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 96:997-1005. 2011
    ..We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras and other farnesylated proteins...
  57. ncbi Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
    Vivek Subbiah
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, Texas 77030, USA
    Mol Cancer Ther 11:2541-6. 2012
    ....
  58. ncbi Molecular imaging of Bcr-Abl phosphokinase in a xenograft model
    Ji Yuan Wu
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Unit 455, P O Box 301402, Houston, TX 77030, USA
    Mol Cancer Ther 8:703-10. 2009
    ..This technique may therefore be useful in the clinic to detect the presence of phosphokinase activity and for early prediction of response...
  59. ncbi Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies
    Apostolia-Maria Tsimberidou
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:574-80. 2004
    ..CONCLUSIONS: IFN-alpha and isotretinoin combination therapy had antitumor activity and was well tolerated in heavily pretreated patients with lymphoid malignancies...
  60. ncbi Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses
    Hillary H Wu
    Department of Bioimmunotherapy, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:2410-9. 2003
    ..These results indicate that early-acting growth factors can induce durable, multilineage responses in a subset of individuals with bone marrow failure...
  61. ncbi Reproducibility of CT perfusion parameters in liver tumors and normal liver
    Chaan S Ng
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, 1400 Pressler St, Unit 1473, Houston, TX 77030 4009, USA
    Radiology 260:762-70. 2011
    ..To assess the reproducibility of computed tomographic (CT) perfusion measurements in liver tumors and normal liver and effects of motion and data acquisition time on parameters...
  62. ncbi Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience
    Hazem El-Osta
    Department of Investigational Therapeutics, Phase 1 Program Unit 455, Division of Cancer Medicine, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 16:1292-8. 2011
    ..Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies...
  63. ncbi Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers
    Fadi Braiteh
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine and Quantitative Sciences, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 14:6296-301. 2008
    ..On the basis of this evidence, we conducted a phase I study of the combination of 5-AZA and valproic acid in patients with advanced cancers...
  64. ncbi Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein ki
    Doris R Siwak
    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 104:879-90. 2005
    ..CONCLUSIONS: Curcumin has potent antiproliferative and proapoptotic effects in melanoma cells. These effects were associated with the suppression of NF-kappaB and IKK activities but were independent of the B-Raf/MEK/ERK and Akt pathways...
  65. ncbi Effect of sampling frequency on perfusion values in perfusion CT of lung tumors
    Chaan S Ng
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Unit 1473, 1400 Pressler St, Houston, TX 77030 4009, USA
    AJR Am J Roentgenol 200:W155-62. 2013
    ..The purpose of this study was to assess as a potential means of limiting radiation exposure the effect on perfusion CT values of increasing sampling intervals in lung perfusion CT acquisition...
  66. ncbi PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors...
  67. ncbi Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors
    Apostolia Maria Tsimberidou
    Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Chemother Pharmacol 65:235-41. 2010
    ..This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling...
  68. ncbi Effect of dual vascular input functions on CT perfusion parameter values and reproducibility in liver tumors and normal liver
    Chaan S Ng
    Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Comput Assist Tomogr 36:388-93. 2012
    ..To assess the impact on absolute values and reproducibility of adding portal venous (PV) to arterial input functions in computed tomographic perfusion (CTp) evaluations of liver tumors and normal liver...
  69. ncbi Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis
    Apostolia M Tsimberidou
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Hepatogastroenterology 59:960-4. 2012
    ..We conducted a phase I trial of IP oxaliplatin and paclitaxel with IV paclitaxel and bevacizumab in patients with peritoneal carcinomatosis...
  70. ncbi Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 10:1300-7. 2011
    ..HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m(2) or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases...
  71. ncbi Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics a Phase 1 Program, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Cancer 115:1091-9. 2009
    ....
  72. ncbi Timing of palliative care referral and symptom burden in phase 1 cancer patients: a retrospective cohort study
    David Hui
    Department of Palliative Care and Rehabilitation Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4402-9. 2010
    ..In the current study, the timing of referral and symptom burden between patients referred to palliative care by phase 1 oncologists and those referred by non-phase 1 oncologists were compared...
  73. ncbi Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:3547-52. 2011
    ..This study assessed outcomes of individuals with advanced cancer who required admission to an intensive care unit (ICU) after referral for an early clinical trial because they did not respond to conventional therapy...
  74. ncbi Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas
    Apostolia-Maria Tsimberidou
    Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Am Acad Dermatol 51:200-4. 2004
    ..CONCLUSION: This pilot study suggests that etanercept is safe and generally well tolerated in patients with CTCL. The effect of etanercept in a larger cohort of patients with early disease merits investigation...
  75. ncbi PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  76. ncbi Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience
    Apostolia Maria Tsimberidou
    Investigational Cancer Therapeutics and Quantitative Sciences Division, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 17:4110-8. 2011
    ..Patients with brain metastases are often excluded from clinical trials, but it is unclear whether they pose an enhanced risk...
  77. ncbi Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse
    Rajul K Jain
    Department of Investigational Cancer Therapeutics, Phase I Program, MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 16:1289-97. 2010
    ..However, a substantial portion of oncology trials now investigate targeted agents, which may have different dose-response relationships than cytotoxic chemotherapies...
  78. ncbi Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series
    Apostolia-Maria Tsimberidou
    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 100:342-9. 2004
    ..A transient early "flare" of disease was observed in some responders. CONCLUSIONS: At these doses, pentostatin was reasonably well tolerated and is an effective drug for the treatment of T-cell lymphomas...
  79. ncbi Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides
    Putao Cen
    Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Acad Dermatol 58:382-6. 2008
    ..29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer...
  80. ncbi Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
    Apostolia Maria Tsimberidou
    Phase 1 Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1507-16. 2011
    ..Midazolam and omeprazole are primarily metabolized by CYP3A4 and CYP2C19, respectively. We evaluated the inhibitory effects of patupilone on the CYP3A4/CYP2C19 pathways...
  81. ncbi A first-in-human study of conatumumab in adult patients with advanced solid tumors
    Roy S Herbst
    Head and Neck Head and Neck Medical Oncology and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:5883-91. 2010
    ..To determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of conatumumab, an investigational, fully human monoclonal agonist antibody against human death receptor 5, in patients with advanced solid tumors...
  82. ncbi Chemotherapy resistance and retreatment: a dogma revisited
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston
    Clin Colorectal Cancer 9:E1-4. 2010
    ..Herein, we report several cases in which retreatment with drugs that had failed earlier in the disease trajectory caused renewed tumor regression. The possible biologic underpinnings that might explain this phenomenon are discussed...
  83. ncbi Phase II trial of curcumin in patients with advanced pancreatic cancer
    Navneet Dhillon
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:4491-9. 2008
    ..We evaluated the clinical biological effects of curcumin (diferuloylmethane), a plant-derived dietary ingredient with potent nuclear factor-kappaB (NF-kappaB) and tumor inhibitory properties, against advanced pancreatic cancer...
  84. ncbi Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides
    Grace Sun
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Am Acad Dermatol 60:231-5. 2009
    ..Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, is most often seen in middle-aged to elderly men...
  85. ncbi The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines
    Mi Ae Lyu
    Immunopharmacology and Targeted Therapy Laboratory, Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0044, Houston, TX 77030, USA
    Biochem Pharmacol 75:836-46. 2008
    ..Delivery of the cytokine TNF to HER-2/neu expressing pancreatic tumor cells, which are inherently resistant to TNF using scFv23/TNF may be an effective therapy for pancreatic cancer especially when utilized in combination with 5-FU...
  86. ncbi Farnesyltransferase inhibitors
    Razelle Kurzrock
    The University of Texas M. D. Anderson Cancer Center, TX, USA
    Clin Adv Hematol Oncol 3:161-2. 2005
  87. ncbi Molecular epidemiology, cancer-related symptoms, and cytokines pathway
    Cielito C Reyes-Gibby
    Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Lancet Oncol 9:777-85. 2008
    ..Likewise, they could identify subgroups who might benefit most from symptom intervention, and contribute to developing personalized and more effective therapies for persistent symptoms...
  88. ncbi Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience
    Sushma Vemulapalli
    Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Am J Hematol 84:408-13. 2009
    ..A prognostic score that can be used to predict time to development of and frequency of VTE is proposed. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  89. ncbi Development of curcumin as an epigenetic agent
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4670-6. 2010
    ..The development of curcumin as an epigenetic agent warrants further preclinical and clinical studies to explore its diversity and efficacy in cancer treatment and in combination with other anticancer agents...
  90. ncbi Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome
    Razelle Kurzrock
    Departments of Bioimmunotherapy, Medicine, and Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 39:20-4. 2002
    ....
  91. ncbi Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma
    Madeleine Duvic
    Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    Clin Lymphoma Myeloma 7:51-8. 2006
    ..The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL)...
  92. ncbi Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model
    Claire M Mach
    Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, U S A
    Anticancer Res 29:1895-9. 2009
    ..This study was designed to determine the minimum effective dose (MED) as well as the optimal dosing schedule of liposomal curcumin in a xenograft mouse model of human pancreatic cancer...
  93. ncbi Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Thoracic Head and Neck Medicine Clinic, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 28:2839-46. 2010
    ..To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer...
  94. ncbi Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis
    Lan Li
    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2351-62. 2004
    ..These effects were accompanied by marked growth inhibition and apoptosis. Through these findings, the authors provided a biologic rationale for the treatment of patients with pancreatic carcinoma using this nontoxic phytochemical...
  95. ncbi Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis
    Behnam Ebrahimi
    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2727-36. 2004
    ..Furthermore, serum cytokine levels, in particular IL-6, may be a useful prognostic marker...
  96. ncbi Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma
    Madeleine Duvic
    Division of Internal Medicine, Department of Dermatology, University of Texas M. D. Anderson Cancer Center, Houston 77030-4095, USA
    J Am Acad Dermatol 49:35-49. 2003
    ....
  97. ncbi Castleman's disease: from basic mechanisms to molecular therapeutics
    Hazem E El-Osta
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, Unit 455, P O Box 301402, Houston, Texas 77030, USA
    Oncologist 16:497-511. 2011
    ..In this article, we review the current state of the art of our understanding of Castleman's disease and its treatment and we provide insight into future treatment strategies based on disease biology...
  98. ncbi Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome
    Daniel J Lenihan
    Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, USA
    Blood 104:655-8. 2004
    ..The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation...
  99. ncbi Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies
    Jorge E Cortes
    Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 39:26-30. 2002
    ....
  100. ncbi Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53
    Laura S Angelo
    Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 62:932-40. 2002
    ..These data suggest that: (a) mutation of p53 contributes to the overexpression of IL-6 in RCC; and (b) wt p53 represses IL-6 expression, at least in part, by interfering with specific transcription factor binding to the IL-6 promoter...
  101. ncbi Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview
    Fedricker D Barber
    Department of Bioimmunotherapy, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 422, Houston, TX 77030, USA
    Cancer Treat Rev 30:425-36. 2004
    ..A variety of agents other than 5-FU have also been given by HAI to patients with liver metastases from diverse cancers. Such regional therapy often yields encouraging response rates and impact on survival therefore merits investigation...

Research Grants5

  1. Farnesyltransferase Inhibitor Therapy for Myelodysplasia
    Razelle Kurzrock; Fiscal Year: 2002
    ....
  2. Exploratory Trial of Curcumin in Pancreatic Cancer
    Razelle Kurzrock; Fiscal Year: 2005
    ..These studies should provide the foundation for the development of curcumin as an anticancer agent and may lead to a novel approach to the management of pancreatic cancer. ..
  3. Phase I Studies of Targeted Anti-Cancer Therapies
    Razelle Kurzrock; Fiscal Year: 2007
    ....